Life Technologies Supports Global Effort to Help Accelerate Emergency Screening of Avian Influenza (H7N9) Virus

CARLSBAD, Calif., April 26, 2013—Life Technologies Corporation (NASDAQ: LIFE) announces that its Applied Biosystems® 7500 Fast Dx Real-Time PCR instrument is indicated for use with the CDC A/H7 Assay, which has received Emergency Use Authorization for detection in patient specimens of the novel influenza A (H7/N9) virus. To date the virus has led to 35 deaths in China and Taiwan.

The CDC's Influenza A/H7 (Eurasian Lineage) Real-Time RT-PCR Diagnostic Assay has received Emergency Use Authorization for detection in patient specimens of the novel influenza A (H7/N9) virus. This test has been authorized only for the diagnosis of A (H7N9) influenza virus and not for the diagnosis of any other viruses or pathogens. Life Technologies' Applied Biosytems 7500 Fast Dx Real-Time PCR instrument is the sole platform indicated for use with the CDC A/H7 Assay. Additionally, the CDC A/H7 Assay can be performed using Life's SuperScript III One-Step qRT-PCR reagent kit. The CDC A/H7 Assay is intended to quickly monitor the spread of the pathogen and thwart a potential pandemic. To support this global need, Life Technologies is increasing production of its reagents and shipping them to labs around the world.

The CDC A/H7 Assay has not been FDA cleared or approved, nor has FDA determined, as permitted under section 564(m) of the Act, that this test may be performed in settings with certificates of waiver under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a.

The CDC A/H7 Assay is only authorized for the duration of the declaration of emergency under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C § 360bbb-#(b)(1), unless the authorization is revoked sooner and the declaration of emergency will terminate when the HHS Secretary determines that the circumstances of a significant potential for a public health emergency have ceased to exist or when there is a change in the approval status of the CDC A/H7 Assay such that the authorization of emergency use is no longer needed, whichever occurs earlier.

Life Technologies has a strong history of working with the CDC, the World Health Organization (WHO) and public health labs to combat virus outbreaks:

  • 2009 – Life Technologies formed a special 24-hour-a-day task force to respond to global requests for assistance with the H1N1 outbreak.
  • 2011 – Life Technologies developed a custom assay to accurately detect the E. coli bacterium that spread through Europe. The assay was developed after company researchers, using samples supplied by scientists at University Hospital Munster, completed the DNA sequencing and analysis work on the deadly E. coli strain using the Ion PGM™ Sequencer.
  • 2012 – Life Technologies established the Global Influenza Network, a partnership of scientists at a number of the world's leading government public health organizations, veterinary agencies and research institutes who collaborate in an effort to increase the speed and efficiency of influenza monitoring and vaccine development.

"We have learned through our past experiences that a strong surveillance program is crucial in times like these," said Dan Didier, Public Health Director for Life Technologies. "We are working continually with our partners around the globe on improving our capabilities, particularly when it comes to developing rapid detection kits."

Cases of the H7N9 virus have been reported out of China and Taiwan only. First cases of the human virus were confirmed in March with more than 100 cases.

The SuperScript III One-Step qRT-PCR kit is for research use only; not for use in diagnostic procedures.

About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

Media Contact:
Patty Zamora
760-476-7818
patty.zamora@lifetech.com